Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2007

Open Access 01-12-2007 | Research article

Duloxetine in the treatment of major depressive disorder: an open-label study

Authors: James I Hudson, David G Perahia, Inmaculada Gilaberte, Fujun Wang, John G Watkin, Michael J Detke

Published in: BMC Psychiatry | Issue 1/2007

Login to get access

Abstract

Background

Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher rates of remission compared with those acting upon a single neurotransmitter. In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined.

Methods

Patients (N = 533) meeting DSM-IV criteria for MDD received open-label duloxetine (60 mg once a day [QD]) for 12 weeks during the initial phase of a relapse prevention trial. Patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score ≥18 and a Clinical Global Impression of Severity (CGI-S) score ≥4 at baseline. Efficacy measures included the HAMD17 total score, HAMD17 subscales, the CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQ-SS). Quality of life was assessed using the Sheehan Disability Scale (SDS) and the Quality of Life in Depression Scale (QLDS). Safety was evaluated by recording spontaneously-reported treatment-emergent adverse events, changes in vital signs and laboratory analytes, and the Patient Global Impression of Sexual Function (PGI-SF) scale.

Results

The rate of discontinuation due to adverse events was 11.3%. Treatment-emergent adverse events reported by ≥10% duloxetine-treated patients were nausea, headache, dry mouth, somnolence, insomnia, and dizziness. Following 12 weeks of open-label duloxetine therapy, significant improvements were observed in all assessed efficacy and quality of life measures. In assessments of depression severity (HAMD17, CGI-S) the magnitude of symptom improvement continued to increase at each study visit, while for painful physical symptoms the onset of improvement was rapid and reached a maximum after 2 to 3 weeks of treatment.

Conclusion

In this open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown to be safe and effective in the treatment of MDD.

Trial registration

NCT00036309.
Appendix
Available only for authorised users
Literature
1.
Greden JF: The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry. 2001, 62 (Suppl 22): 5-9.PubMed
2.
Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J: The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989, 262: 914-919. 10.1001/jama.262.7.914.CrossRefPubMed
3.
Anderson IM, Tomenson BM: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ. 1995, 310: 1433-1438.CrossRefPubMedPubMedCentral
4.
Steffens DC, Krishnan KR, Helms MJ: Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997, 6: 10-18. 10.1002/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9.CrossRefPubMed
5.
Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000, 58: 19-36. 10.1016/S0165-0327(99)00092-0.CrossRefPubMed
6.
Corey-Lisle PK, Nash R, Stang P, Swindle R: Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004, 164: 1197-1204. 10.1001/archinte.164.11.1197.CrossRefPubMed
7.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001, 25: 871-880. 10.1016/S0893-133X(01)00298-6.CrossRefPubMed
8.
Wong DT, Bymaster FP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?. Prog Drug Res. 2002, 58: 169-222.CrossRefPubMed
9.
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002, 63: 308-315.CrossRefPubMed
10.
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002, 36: 383-10.1016/S0022-3956(02)00060-2.CrossRefPubMed
11.
Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002, 63: 225-231.CrossRefPubMed
12.
Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004, 24: 389-399. 10.1097/01.jcp.0000132448.65972.d9.CrossRefPubMed
13.
Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry. 2003, 5: 19-28.CrossRefPubMedPubMedCentral
14.
Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002, 36: 106-132.PubMed
15.
Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ: Duloxetine in the prevention of relapse of major depressive disorder. Br J Psychiatry. 2006, 188: 346-353. 10.1192/bjp.188.4.346.CrossRefPubMed
16.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 1994, Washington, DC: American Psychiatric Association, 4
17.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998, 59 (Suppl 20): 22-33.PubMed
18.
19.
Guy W: ECDEU assessment manual for psychopharmacology, revised 1976. 1976, Rockville, MD: National Institutes of Mental Health
20.
JNC: The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. 1997, NIH Publication No. 98-4080.
21.
Michelson D, Schmidt M, Lee J, Tepner R: Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther. 2001, 27: 289-302. 10.1080/009262301750257146.CrossRefPubMed
22.
DeLoach LJ, Higgins MS, Caplan AB, Stiff JL: The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998, 86: 102-106. 10.1097/00000539-199801000-00020.PubMed
23.
Kellner R: A symptom questionnaire. J Clin Psychiatry. 1987, 48: 268-274.PubMed
24.
Hunt SM, McKenna SP: The QLDS: a scale for the measurement of quality of life in depression. Health Policy. 1992, 22: 307-319. 10.1016/0168-8510(92)90004-U.CrossRefPubMed
25.
Sheehan DV, Harnett-Sheehan K, Raj BA: The measurement of disability. Int Clin Psychopharmacol. 1996, 11 (Suppl 3): 89-95. 10.1097/00004850-199606003-00015.CrossRefPubMed
26.
Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD: Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003, 53: 754-760. 10.1016/S0006-3223(02)01867-X.CrossRefPubMed
27.
Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G: Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003, 13: 179-190. 10.1081/BIP-120019265.CrossRefPubMed
28.
29.
30.
31.
Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005, 66: 686-692.CrossRefPubMed
32.
Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005, 20: 327-341. 10.1002/hup.696.CrossRefPubMed
33.
Agelink MW, Ullrich H, Baumann B, Strum S, Majewski T: Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data. Psychopharmacology (Berl). 2002, 163: 151-156. 10.1007/s00213-002-1146-7.CrossRef
34.
Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004, 65: 1190-1196.CrossRefPubMed
35.
Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003, 64: 1237-1244.CrossRefPubMed
36.
37.
38.
Richardson BP: Serotonin and nociception. Ann NY Acad Sci. 1990, 600: 511-519. 10.1111/j.1749-6632.1990.tb16906.x.CrossRefPubMed
39.
Willis WD, Westlund KN: Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol. 1997, 14: 2-31. 10.1097/00004691-199701000-00002.CrossRefPubMed
40.
Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004, 45 (1): 17-28. 10.1176/appi.psy.45.1.17.CrossRefPubMed
41.
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry. 2004, 65: 521-530.CrossRefPubMed
Metadata
Title
Duloxetine in the treatment of major depressive disorder: an open-label study
Authors
James I Hudson
David G Perahia
Inmaculada Gilaberte
Fujun Wang
John G Watkin
Michael J Detke
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2007
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-7-43

Other articles of this Issue 1/2007

BMC Psychiatry 1/2007 Go to the issue

Research article

Web-based tools can be used reliably to detect patients with major depressive disorder and subsyndromal depressive symptoms

Research article

Depression in the elderly: Does family system play a role? A cross-sectional study

Research article

Suicidal ideation and associated factors among school-going adolescents in rural Uganda

Research article

Serotonin transporter binding of [123I]ADAM in bulimic women, their healthy twin sisters, and healthy women: a SPET study

Study protocol

Internet-based treatment for adults with depressive symptoms: the protocol of a randomized controlled trial

Research article

Early onset of treatment effects with oral risperidone